Chemotherapy for malignant mesothelioma
- 1 August 1982
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 5 (4) , 429-432
- https://doi.org/10.1097/00000421-198208000-00014
Abstract
Twelve patients with a tissue diagnosis of malignant mesothelioma were treated with combination chemotherapy (CAMEO) every 4-5 wk, with or without hemithoracic radiation. Mean survival from the time of tissue diagnosis and start of protocol treatment was 15.7 and 12.6 mo., respectively. Median survival from the time of tissue diagnosis and start of protocol treatment was 11 and 6.5 mo., respectively. Two patients were long-term survivors (32 and 45 mo.), one of whom is alive without evidence of recurrent disease. Toxicity from this regimen was moderate.This publication has 3 references indexed in Scilit:
- Multimodality therapy for malignant mesothelioma based on a study of natural historyThe American Journal of Medicine, 1980
- The value of adriamycin in the treatment of diffuse malignant pleural mesotheliomaCancer, 1978
- Chemotherapy of malignant diffuse mesotheliomaCancer, 1976